Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

See Remarks

Chief Development Officer

Chief Financial Officer

Chief Business Officer

Chief Accounting Officer

Chief Scientific Officer

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrin...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-10	Premium	sold (taxes)	Premium	Premium	Premium	-
2024-04-10	Premium	sold	Premium	Premium	Premium	-
2024-04-10	Premium	acquired	Premium	Premium	Premium	-
2024-04-10	Premium	acquired	Premium	Premium	Premium	-
2024-04-04	Premium	sold	Premium	Premium	Premium	See Remarks
2024-04-04	Premium	acquired	Premium	Premium	Premium	See Remarks
2024-04-01	Premium	sold	Premium	Premium	Premium	See Remarks
2024-04-01	Premium	acquired	Premium	Premium	Premium	See Remarks
2024-04-01	Premium	sold	Premium	Premium	Premium	-
2024-04-01	Premium	acquired	Premium	Premium	Premium	-
2024-03-27	Premium	acquired	Premium	Premium	Premium	See Remarks
2024-03-27	Premium	sold	Premium	Premium	Premium	See Remarks
2024-03-19	Premium	acquired	Premium	Premium	Premium	See Remarks
2024-03-18	Premium	acquired	Premium	Premium	Premium	See Remarks
2024-03-18	Premium	sold	Premium	Premium	Premium	See Remarks
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Development Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	Chief Business Officer
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Business Officer
2024-03-01	Premium	sold	Premium	Premium	Premium	-
2024-03-01	Premium	acquired	Premium	Premium	Premium	See Remarks
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Accounting Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	Chief Accounting Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	-
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer

CORT - Corcept Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for CORT